Coldstream Capital Management Inc. Purchases 1,143 Shares of Danaher Co. (NYSE:DHR)

Coldstream Capital Management Inc. grew its position in Danaher Co. (NYSE:DHR) by 8.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,299 shares of the conglomerate’s stock after purchasing an additional 1,143 shares during the quarter. Coldstream Capital Management Inc.’s holdings in Danaher were worth $3,822,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Gilbert & Cook Inc. lifted its position in shares of Danaher by 4.9% in the fourth quarter. Gilbert & Cook Inc. now owns 1,830 shares of the conglomerate’s stock valued at $423,000 after acquiring an additional 86 shares in the last quarter. Accretive Wealth Partners LLC grew its holdings in Danaher by 12.9% during the 4th quarter. Accretive Wealth Partners LLC now owns 3,632 shares of the conglomerate’s stock valued at $840,000 after buying an additional 414 shares in the last quarter. Gryphon Financial Partners LLC raised its position in shares of Danaher by 19.1% during the fourth quarter. Gryphon Financial Partners LLC now owns 2,917 shares of the conglomerate’s stock valued at $675,000 after buying an additional 468 shares during the last quarter. Versor Investments LP purchased a new position in shares of Danaher in the fourth quarter worth $255,000. Finally, Jump Financial LLC boosted its position in shares of Danaher by 287.0% during the fourth quarter. Jump Financial LLC now owns 4,625 shares of the conglomerate’s stock worth $1,070,000 after acquiring an additional 3,430 shares during the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Stock Up 0.6 %

Shares of NYSE DHR opened at $274.72 on Wednesday. The company has a market cap of $198.41 billion, a P/E ratio of 46.56, a PEG ratio of 4.38 and a beta of 0.83. The firm has a 50-day simple moving average of $262.56 and a two-hundred day simple moving average of $256.11. Danaher Co. has a 1 year low of $182.09 and a 1 year high of $281.70. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. The firm had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. Danaher’s quarterly revenue was down 2.9% compared to the same quarter last year. During the same period last year, the company earned $2.05 EPS. Research analysts anticipate that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be issued a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.39%. Danaher’s payout ratio is presently 18.31%.

Analyst Ratings Changes

A number of analysts have issued reports on DHR shares. Leerink Partners lifted their price target on shares of Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $300.00 price objective on shares of Danaher in a research note on Friday, September 6th. Bank of America upped their price objective on Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. Finally, Jefferies Financial Group initiated coverage on shares of Danaher in a report on Monday, June 3rd. They issued a “buy” rating and a $295.00 target price for the company. Seven equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $278.94.

Insider Buying and Selling

In other Danaher news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The transaction was disclosed in a filing with the SEC, which is available through this link. In other news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Brian W. Ellis sold 9,600 shares of the stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $5,566,486.80. The disclosure for this sale can be found here. Insiders have sold 39,659 shares of company stock valued at $11,042,433 in the last 90 days. Company insiders own 11.10% of the company’s stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.